Objective: To investigate the clinical effect of Yisui Bushen formula in improving malignant lymphoma chemotherapy-related anemia and immune function. Method: Totally 110 cases of malignant lymphoma chemotherapy-related anemia patients treated in our Haematology Department from January 2010 to December 2015 were selected and randomly divided into treatment group and control group according to random number table method

with 55 cases in each group. The control group was given conventional chemotherapy

while the treatment group was given Yisui Bushen formula for oral treatment (1/d) in addition to conventional chemotherapy. One course of treatment was 15 days

and they received 2 courses of treatment. Blood routine examination was performed

and the quality of life

clinical curative effect and complications of the two groups were observed and compared. Result: The total effective rate of the control group was 69.09%

whereas the total effective rate of the treatment group was 89.09%

indicating a statistically significant difference (P<0.05). Compared with before treatment

hemoglobin (Hb)

hematocrit (Hct)

red blood cell (RBC) content of the two groups increased after treatment (P<0.05)

while the recombinant human erythropoietin (EPO) content reduced

suggesting statistically significant differences (P<0.05). After treatment

scores of body

role

social

emotional

and other indicators were increased

indicating statistically significant differences (P<0.05). The effectiveness of treatment group was 87.80%

which was higher than 68.29% of control group (P<0.05). After treatment

the levels of CD3+

CD4+

CD4+/CD8+ and CD8+ cells in treatment group were significantly lower than those in control group (P<0.05). The incidence of adverse reactions of control group was 12.73%

whereas the incidence of adverse reactions of treatment group was 7.27%

indicating a statistically significant difference in adverse reactions between two groups (P<0.05). Conclusion: Yisui Bushen formula shows an obvious clinical effect in improving malignant lymphoma chemotherapy-related anemia

the quality of life and immune function

with good synergy and attenuation.